Group 1 - The core point of the news is that Haixi Pharmaceutical (HK02637) has announced a delay in its IPO after completing dark pool trading, which is a rare occurrence in the Hong Kong stock market [1] - The company did not disclose the specific reasons for the delay, but it is noted that such situations are uncommon, with the last similar case occurring in October 2022 involving another company [1] - Haixi Pharmaceutical's dark pool trading showed strong performance, with a subscription multiple exceeding 2400 times and total subscription amount over 240 billion HKD [1] Group 2 - Haixi Pharmaceutical, established in March 2012 and headquartered in Fuzhou, Fujian Province, operates in both generic and innovative drug development, with a focus on commercialized products for various diseases [2] - The company has 14 approved generic drugs, four of which are included in the national procurement list, and five additional drugs are in the ANDA stage, expected to receive market approval by 2025 or 2026 [2] - Revenue figures for Haixi Pharmaceutical during the reporting periods are approximately 212 million CNY, 317 million CNY, 467 million CNY, and 249 million CNY, with net profits of approximately 69 million CNY, 117 million CNY, 136 million CNY, and 90 million CNY respectively [2] Group 3 - The founders of Haixi Pharmaceutical are Dr. Kang Xinshan and his spouse Feng Yan, who together control 41.17% of the company's shares through direct and indirect means [3]
已暗盘交易，收涨24.54% 上市前夜海西新药突然宣布延迟上市